- Home
- LYRA vs BLRX Comparison
LYRA vs BLRX Comparison
Compare LYRA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- BLRX
- Stock Information
- Founded
- LYRA 2005
- BLRX 2003
- Country
- LYRA United States
- BLRX Israel
- Employees
- LYRA N/A
- BLRX N/A
- Industry
- LYRA Medical/Dental Instruments
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- BLRX Health Care
- Exchange
- LYRA Nasdaq
- BLRX Nasdaq
- Market Cap
- LYRA 15.0M
- BLRX 17.0M
- IPO Year
- LYRA 2020
- BLRX 2011
- Fundamental
- Price
- LYRA $7.05
- BLRX $3.71
- Analyst Decision
- LYRA Buy
- BLRX Strong Buy
- Analyst Count
- LYRA 2
- BLRX 2
- Target Price
- LYRA $16.00
- BLRX $19.00
- AVG Volume (30 Days)
- LYRA 28.3K
- BLRX 40.4K
- Earning Date
- LYRA 08-12-2025
- BLRX 08-14-2025
- Dividend Yield
- LYRA N/A
- BLRX N/A
- EPS Growth
- LYRA N/A
- BLRX N/A
- EPS
- LYRA N/A
- BLRX N/A
- Revenue
- LYRA $770,000.00
- BLRX $17,251,000.00
- Revenue This Year
- LYRA N/A
- BLRX N/A
- Revenue Next Year
- LYRA $139.18
- BLRX N/A
- P/E Ratio
- LYRA N/A
- BLRX N/A
- Revenue Growth
- LYRA N/A
- BLRX 1.19
- 52 Week Low
- LYRA $3.81
- BLRX $2.30
- 52 Week High
- LYRA $37.50
- BLRX $32.26
- Technical
- Relative Strength Index (RSI)
- LYRA 41.94
- BLRX 39.17
- Support Level
- LYRA $6.51
- BLRX $3.58
- Resistance Level
- LYRA $7.57
- BLRX $4.17
- Average True Range (ATR)
- LYRA 0.55
- BLRX 0.27
- MACD
- LYRA 0.14
- BLRX -0.01
- Stochastic Oscillator
- LYRA 47.71
- BLRX 37.11
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.